Stay Updated
For all press requests, please reach out to [email protected].
News and Reports
Blood Journal: Next-generation multiple myeloma treatment: a pharmacoeconomic perspective
May 2 Drs. S. Vincent Rajkumar and Jean Luc Harousseau Drs. Vincent Rajkumar and Jean Luc Harousseau are celebrated multiple myeloma doctors. Multiple myeloma is an incurable blood cancer that can be treated with very expensive drugs. Rajkumar and Harousseau explain the impact of high drug prices on patients, and what can be done to […]
News and Reports
The Financial Times: Celgene to Partner Jounce in Battle Against Cancer
May 1 David Crow Celgene, the acquisitive US biotech company, has signed a deal worth up to $2.6bn with a cancer start-up to develop a new generation of drugs that try to turn the body into a weapon against tumours. The partnership with privately owned Jounce Therapeutics is the latest in a flurry of bets […]
News and Reports
Politico Pro: Trump Could Turn to Drug Prices After Obamacare Defeat
March 31 Sarah Karlin-Smith Pharma stayed out of the bruising fight over Obamacare repeal, but the bill’s demise could turn into the industry’s worst nightmare: a big bipartisan fight over drug prices, with President Donald Trump leading the charge. Trump, who has repeatedly promised action on drug prices, is looking for a policy win after […]
News and Reports
Forbes: A Patient's Optimistic Call For Bipartisan Drug-Pricing Reform
March 27,2017 David Mitchell With our nation’s fight over the Affordable Care Act in the rear-view mirror, it’s time for Donald Trump and Congress to focus on a genuinely bipartisan issue: drug prices. According to the Kaiser Family Foundation, 8 in 10 Americans want to allow the government to negotiate prices for people on Medicare. […]
News and Reports
Kaiser Health News: "As Drug Costs Soar, People Delay Or Skip Cancer Treatments"
March 15,2017 Liz Szabo John Krahne received alarming news from his doctor last December. His brain tumors were stable, but his lung tumors had grown noticeably larger. The doctor recommended a drug called Alecensa, which sells for more than $159,000 a year. Medicare would charge Krahne a $3,200 copay in December, then another $3,200 in […]
News and Reports
Health Affairs Blog: "R&D Costs For Pharmaceutical Companies Do Not Explain Elevated US Drug Prices"
Summary from P4AD: New research debunks the claim that drug corporations must charge U.S. patients high prices to fund new drugs. The research from doctors at Memorial Sloan Kettering Cancer Center is clear: Drug corporations could cut U.S. prices significantly and still cover the full cost the companies claim for research for the entire world. […]
News and Reports
Morning Consult: “How Patients Will Take on the Rigged System for Drug Pricing"
March 6, 2017 David Mitchell Every Tuesday for the past nine weeks, I’ve sat in an infusion room for four-and-half hours receiving drugs that cost $13,000. It’s going to be every other Tuesday for the next 14 weeks. Total value of the deal — $208,000. I am very grateful for these drugs. I relapsed months […]
News and Reports
Blooomberg: “Drug Costs Too High? Fire the Middleman"
March 3, 2017 Neil Weinberg and Robert Langreth A decade ago, Caterpillar Inc. looked at its employee drug plan and sensed that money was evaporating. The bills for pills had increased inexorably, so the company started to rein in its pharmacy benefit manager, or PBM. The managers are middlemen with murky incentives behind their decisions […]